Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
life sciences
merck
4
×
national
4
×
national blog main
national top stories
new york blog main
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
bristol-myers squibb
cell therapy
diagnostics
eli lilly
fda
immunotherapy
medicare
migraine
What
new
4
×
drug
approved
bio
fda
roundup
adults
advantages
allergan
approval
bar
biogen’s
biopharmaceutical
brings
cancer
class
companies
convo
deeper
dna
earlier
expect
failures
fingerprint
gamble
genetic
going
littered
market
matter
medco’s
medicine
medicines
migraine
monday
mover
nash
nd
news
nod
Language
unset
Current search:
merck
×
new
×
national
×
@xconomy.com
4 years ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues